Bao You-Yuan, Pan Lai-Sheng, Cao Yong, Wu Jie, Xie Shen-Hao, Ouyang Feng, Tan Jian, Wang Qi-Fa, Zhou Dong-Wei, Tang Bin, Hong Tao
2Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Departments of1Neurosurgery.
J Neurosurg. 2024 Sep 20;142(2):464-474. doi: 10.3171/2024.5.JNS232533. Print 2025 Feb 1.
Craniopharyngiomas (CPs) in adults are rare benign epithelial tumors, and few contemporary studies have explored outcomes after surgical treatment in elderly patients, especially with regard to endoscopic endonasal surgery (EES).
A retrospective cohort study was conducted on patients aged ≥ 18 years with CP who were treated with EES from 2013 to 2022. The cohort was divided into nonelderly (18-64 years) and elderly (≥ 65 years) groups based on age. Various parameters, including patient and tumor characteristics, surgical outcomes, complications, and follow-up, were compared between the two age groups.
A total of 193 patients met the inclusion criteria, with 161 (83.4%) patients in the nonelderly group and 32 (16.6%) patients in the elderly group. Preoperatively, older patients were more likely to have memory impairment (4.3% vs 18.8%, p = 0.010), fatigue or decreased energy (9.3% vs 34.4%, p = 0.001), hypopituitarism (68.7% vs 90.6%, p = 0.012), or hydrocephalus (18% vs 40.6%, p = 0.005), and they were more likely asymptomatic (1.2% vs 9.4%, p = 0.033) and less likely to experience headache (57.8% vs 31.3%, p = 0.006). Patients in the elderly group had a longer symptom duration (median [IQR] 5 [10] months vs 9.5 [13] months, p = 0.001) and higher comorbidity scores (p < 0.001). Postoperatively, gross-total resection was achieved in 145 (90.1%) and 28 (87.5%) patients in the nonelderly and elderly groups, respectively. Older patients were more likely to develop pneumonia (5% vs 21.9%, p = 0.004). There were no significant differences in the extent of resection (p = 0.541), pathological subtypes (88.2% vs 75.0% adamantinomatous, p = 0.089), operation time (mean ± SD 307.8 ± 68.3 minutes vs 323.5 ± 86.0 minutes, p = 0.257), estimated blood loss (median [IQR] 300 [200] ml vs 300 [238] ml, p = 0.594), length of stay (median [IQR] 15 [8] days vs 15 [22] days, p = 0.964), perioperative mortality (2.5% vs 3.1%, p > 0.99), or postoperative severe hypothalamic dysfunction (37.9% vs 50.0%, p = 0.237) between the groups. Multivariate Cox regression analysis demonstrated that tumor calcification (HR 3.406, 95% CI 1.859-27.233, p = 0.038) and preoperative hydrocephalus (HR 3.688, 95% CI 1.310-10.386, p = 0.013) were independently associated with decreased survival. The median follow-up period in the elderly group was shorter (71 months vs 44 months, p = 0.001), and no recurrence was observed (7.1% vs 0%, p = 0.132).
This study demonstrates that EES is a viable treatment option for older CP patients. With appropriate perioperative management, EES does not significantly increase mortality and, in selected populations, is well tolerated by patients.
成人颅咽管瘤(CP)是罕见的良性上皮性肿瘤,当代很少有研究探讨老年患者手术治疗后的结局,尤其是关于鼻内镜下经鼻手术(EES)。
对2013年至2022年接受EES治疗的年龄≥18岁的CP患者进行回顾性队列研究。根据年龄将队列分为非老年组(18 - 64岁)和老年组(≥65岁)。比较两组患者的各种参数,包括患者和肿瘤特征、手术结局、并发症及随访情况。
共有193例患者符合纳入标准,其中非老年组161例(83.4%),老年组32例(16.6%)。术前,老年患者更易出现记忆障碍(4.3%对18.8%,p = 0.010)、疲劳或精力下降(9.3%对34.4%,p = 0.001)、垂体功能减退(68.7%对90.6%,p = 0.012)或脑积水(18%对百分之40.6,p = 0.005),且更易无症状(1.2%对9.4%,p = 0.033),头痛发生率更低(57.8%对31.3%,p = 0.006)。老年组患者症状持续时间更长(中位数[四分位间距]5[10]个月对9.5[13]个月,p = 0.001),合并症评分更高(p < 0.001)。术后,非老年组和老年组分别有145例(90.1%)和28例(87.5%)患者实现了全切除。老年患者更易发生肺炎(5%对21.9%,p = 0.004)。两组在切除范围(p = 0.541)、病理亚型(造釉细胞瘤型88.2%对75.0%,p = 0.089)、手术时间(均值±标准差307.8±68.3分钟对323.5±86.0分钟,p = 0.257)、估计失血量(中位数[四分位间距]300[200]毫升对300[238]毫升,p = 0.594)、住院时间(中位数[四分位间距]15[8]天对15[22]天,p = 0.964)、围手术期死亡率(2.5%对3.1%,p > 0.99)或术后严重下丘脑功能障碍(37.9%对50.0%,p = 0.237)方面无显著差异。多因素Cox回归分析表明,肿瘤钙化(风险比3.406,95%置信区间1.859 - 27.233,p = 0.038)和术前脑积水(风险比3.——此处原文疑似有误,推测为3.688——,95%置信区间1.310 - 10.386,p = 0.013)与生存率降低独立相关。老年组的中位随访期较短(71个月对44个月,p = 0.001),且未观察到复发(7.1%对0%,p = 0.132)。
本研究表明,EES是老年CP患者可行的治疗选择。通过适当的围手术期管理,EES不会显著增加死亡率,在特定人群中患者耐受性良好。